{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Savid-Frontera C"],"funding":["CCR NIH HHS","Intramural NIH HHS","Secretaria de Ciencia y Tecnología-UNC","Intramural Research Program of the Center for Cancer Research, National Cancer Institute","NCI NIH HHS","Fundación para el Progreso de la Medicina"],"pagination":["115-133"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8739399"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["14(2)"],"pubmed_abstract":["<b>Aim:</b> The aim of this work is to utilize a gene expression procedure to safely express systemic IL-12 and evaluate its effects in mouse tumor models<b>. Materials & methods:</b> Secondary lymphoid organs and tumors from EL4 and B16 tumor-bearing mice were analyzed by supervised and unsupervised methods. <b>Results:</b> IL-12 cDNA induced systemic IL-12 protein levels lower than the tolerated dose in patients. Control of tumor growth was observed in subcutaneous B16 and EL4 tumors. Systemic IL-12 expression induced a higher frequency of both total tumor-infiltrated CD45<sup>+</sup> cells and proliferative IFN-γ<sup>+</sup>CD8<sup>+</sup> T cells along with a lower frequency of CD4<sup>+</sup>FOXP3<sup>+</sup> and CD11b<sup>+</sup>Gr-1<sup>+</sup> cells. <b>Conclusion:</b> This approach characterizes the systemic effects of IL-12, helping to improve treatment of metastases or solid tumors."],"journal":["Immunotherapy"],"pubmed_title":["Safety levels of systemic IL-12 induced by cDNA expression as a cancer therapeutic."],"pmcid":["PMC8739399"],"funding_grant_id":["GC N°1","HHSN261200800001E","HHSN261200800001C","ZIA BC009283","2018-2021","ZIA BC 009283"],"pubmed_authors":["Viano ME","Reynolds D","Matellon M","Baez NS","Savid-Frontera C","Rodriguez-Galan MC","A Young H"],"additional_accession":[]},"is_claimable":false,"name":"Safety levels of systemic IL-12 induced by cDNA expression as a cancer therapeutic.","description":"<b>Aim:</b> The aim of this work is to utilize a gene expression procedure to safely express systemic IL-12 and evaluate its effects in mouse tumor models<b>. Materials & methods:</b> Secondary lymphoid organs and tumors from EL4 and B16 tumor-bearing mice were analyzed by supervised and unsupervised methods. <b>Results:</b> IL-12 cDNA induced systemic IL-12 protein levels lower than the tolerated dose in patients. Control of tumor growth was observed in subcutaneous B16 and EL4 tumors. Systemic IL-12 expression induced a higher frequency of both total tumor-infiltrated CD45<sup>+</sup> cells and proliferative IFN-γ<sup>+</sup>CD8<sup>+</sup> T cells along with a lower frequency of CD4<sup>+</sup>FOXP3<sup>+</sup> and CD11b<sup>+</sup>Gr-1<sup>+</sup> cells. <b>Conclusion:</b> This approach characterizes the systemic effects of IL-12, helping to improve treatment of metastases or solid tumors.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Feb","modification":"2025-04-05T09:03:11.81Z","creation":"2025-04-05T09:03:11.81Z"},"accession":"S-EPMC8739399","cross_references":{"pubmed":["34783257"],"doi":["10.2217/imt-2021-0080"]}}